Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead to Present at Upcoming Scientific Conferences

Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that the company will present data on the Dynamic PolyConjugate™ (DPC) siRNA delivery system and the ARC-520 hepatitis B drug candidate at three upcoming scientific conferences.

Arrowhead to Present at Upcoming Scientific Conferences

Pasadena, CA | Posted on June 13th, 2013

Scheduled conference presentations in June include the following:

The 18th Annual Meeting of the RNA Society - Davos, Switzerland, June 14, 2013

A workshop presentation titled, "Development of Dynamic Polyconjugates for tissue-targeted delivery of siRNA," will be presented by Christine Wooddell, Ph.D., Senior Scientist;

4th RNAi Research & Therapeutics Conference - San Francisco, CA, USA, June 21, 2013

A featured presentation titled, "DPC Technology for siRNA Delivery: Moving from Platform to Pipeline," will be presented by David Lewis, Ph.D., Vice President, Biology;

The European CLINAM and ETPN Summit, Clinical Nanomedicine and Targeted Medicine - Basel, Switzerland, June 26, 2013

An oral presentation titled, "A Novel Hepatitis B Treatment with RNAi," will be presented by Christopher Anzalone, Ph.D., President and CEO.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus infection. The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs.

For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to

For more information, please click here

Contacts:
Arrowhead Research
Vince Anzalone, CFA
626-304-3400

The Trout Group, LLC
Lauren Glaser
646-378-2972

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) September 25th, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

Nanomedicine

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) September 25th, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

Announcements

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) September 25th, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

Events/Classes

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

Arrowhead Pharmaceuticals to Present at Upcoming September 2018 Conferences August 31st, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project